Haag, S, Lindblom, Y, Mjorndal, T, Adolfsson, R.
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol
2006; 21: 93–8.
Nasrallah, HA, Newcomer, JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol
2004; 24 (suppl 1): S7–14.
Santhouse, A, Holloway, F.
Physical health of patients in continuing care. Adv Psychiatr Treat
1999; 5: 455–62.
Management of people with schizophrenia in primary care. Adv Psychiatr Treat
1998; 4: 46–52.
Cohn, TA, Sernyak, MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry
2006; 51: 492–501.
Kendrick, T, Sibbald, B, Burns, T, Freeling, P.
Role of general practitioners in care of long term mentally ill patients. BMJ
1991; 302: 508–10.
O'Brien, SM, Devitt, E, Ahmed, M, McDonald, C.
High prevalence of risk factors for physical illness in a long-stay psychiatric unit. Ir J Psychol Med
2007; 24: 55–8.
National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. NICE, 2002 [updated March 2009] (http://www.nccmh.org.uk/guidelines_schiz_update.html).
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabet Care
2004; 27: 596–601.
Nasrallah, HA, Meyer, JM, Goff, DC, McEvoy, JP, Davis, SM, Stroup, TS, et al. Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res
2006; 86: 15–22.
Bosworth, HB, Calhoun, PS, Stechuchak, KM, Butterfield, MI. Use of psychiatric and medical health care by veterans with severe mental illness. Psychiatr Serv
2004; 55: 708–10.
De Hert, M, Van Eyeck, D, De Nayer, A.
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol
2006; 21: 1–5.
Barnes, TR, Paton, C, Cavanagh, MR, Hancock, E, Taylor, DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull
2007; 33: 1397–403.
Burns, T, Cohen, A.
Item-of-service payments for general practitioner care of severely mentally ill persons: does the money matter? Br J Gen Pract
1998; 48: 1415–6.